Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
Dimebon (latrepirdine)Medivation, in collaboration with Pfizer, is currently evaluating dimebon in both Alzheimer’s and Huntington diseases in multiple clinical trials. We have completed enrollment in the confirmatory Phase 3 CONNECTION trial of dimebon in patients with mild-to-moderate Alzheimer’s disease. The Phase 3 CONCERT study, which is currently enrolling patients, is evaluating dimebon in patients already treated with donepezil, the leading Alzheimer’s disease medication worldwide. We have completed enrollment in a safety trial of patients with Alzheimer’s disease on a variety of anti-dementia medications to help meet international safety database requirements. The Phase 3 CONSTELLATION and CONTACT trials are evaluating dimebon in patients with moderate-to-severe disease. To read about the study results from our first pivotal trial of dimebon in Alzheimer’s disease, please click here. In addition, we are currently enrolling patients in an international safety and efficacy Phase 3 trial known as HORIZON in patients with mild-to-moderate Huntington disease. To read about the study results from our Phase 2 trial of dimebon in Huntington disease, please click here. For more information about our clinical studies, please contact Medivation at This e-mail address is being protected from spambots. You need JavaScript enabled to view it To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.
|
 |
 |
| Medivation © 2010 |